Product: Phospho-NFAT2 (Ser172) Antibody
Catalog: AF8293
Description: Rabbit polyclonal antibody to Phospho-NFAT2 (Ser172)
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Mol.Wt.: 78kDa,101kDa; 101kD(Calculated).
Uniprot: O95644
RRID: AB_2840355

View similar products>>

   Size Price Inventory
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Polyclonal
Specificity:
Phospho-NFAT2 (Ser172) Antibody detects endogenous levels of NFAT2 only when phosphorylated at Ser172.
RRID:
AB_2840355
Cite Format: Affinity Biosciences Cat# AF8293, RRID:AB_2840355.
Conjugate:
Unconjugated.
Purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

cytoplasmic 1; MGC138448; NF ATc; NF ATc1; NF-ATc; NF-ATc1; NF-ATc1.2; NFAC1_HUMAN; NFAT 2; NFAT transcription complex cytosolic component; NFATC 1; NFATc; NFATc1; Nuclear factor of activated T cells cytoplasmic 1; Nuclear factor of activated T cells cytoplasmic calcineurin dependent 1; Nuclear factor of activated T cells cytosolic component 1; nuclear factor of activated T-cells 'c'; Nuclear factor of activated T-cells;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
O95644 NFAC1_HUMAN:

Expressed in thymus, peripheral leukocytes as T-cells and spleen. Isoforms A are preferentially expressed in effector T-cells (thymus and peripheral leukocytes) whereas isoforms B and isoforms C are preferentially expressed in naive T-cells (spleen). Isoforms B are expressed in naive T-cells after first antigen exposure and isoforms A are expressed in effector T-cells after second antigen exposure. Isoforms IA are widely expressed but not detected in liver nor pancreas, neural expression is strongest in corpus callosum. Isoforms IB are expressed mostly in muscle, cerebellum, placenta and thymus, neural expression in fetal and adult brain, strongest in corpus callosum.

Sequence:
MPSTSFPVPSKFPLGPAAAVFGRGETLGPAPRAGGTMKSAEEEHYGYASSNVSPALPLPTAHSTLPAPCHNLQTSTPGIIPPADHPSGYGAALDGGPAGYFLSSGHTRPDGAPALESPRIEITSCLGLYHNNNQFFHDVEVEDVLPSSKRSPSTATLSLPSLEAYRDPSCLSPASSLSSRSCNSEASSYESNYSYPYASPQTSPWQSPCVSPKTTDPEEGFPRGLGACTLLGSPRHSPSTSPRASVTEESWLGARSSRPASPCNKRKYSLNGRQPPYSPHHSPTPSPHGSPRVSVTDDSWLGNTTQYTSSAIVAAINALTTDSSLDLGDGVPVKSRKTTLEQPPSVALKVEPVGEDLGSPPPPADFAPEDYSSFQHIRKGGFCDQYLAVPQHPYQWAKPKPLSPTSYMSPTLPALDWQLPSHSGPYELRIEVQPKSHHRAHYETEGSRGAVKASAGGHPIVQLHGYLENEPLMLQLFIGTADDRLLRPHAFYQVHRITGKTVSTTSHEAILSNTKVLEIPLLPENSMRAVIDCAGILKLRNSDIELRKGETDIGRKNTRVRLVFRVHVPQPSGRTLSLQVASNPIECSQRSAQELPLVEKQSTDSYPVVGGKKMVLSGHNFLQDSKVIFVEKAPDGHHVWEMEAKTDRDLCKPNSLVVEIPPFRNQRITSPVHVSFYVCNGKRKRSQYQRFTYLPANVPIIKTEPTDDYEPAPTCGPVSQGLSPLPRPYYSQQLAMPPDPSSCLVAGFPPCPQRSTLMPAAPGVSPKLHDLSPAAYTKGVASPGHCHLGLPQPAGEAPAVQDVPRPVATHPGSPGQPPPALLPQQVSAPPSSSCPPGLEHSLCPSSPSPPLPPATQEPTCLQPCSPACPPATGRPQHLPSTVRRDESPTAGPRLLPEVHEDGSPNLAPIPVTVKREPEELDQLYLDDVNEIIRNDLSSTSTHS

PTMs - O95644 As Substrate

Site PTM Type Enzyme
R23 Methylation
S117 Phosphorylation
S151 Phosphorylation
S158 Phosphorylation
S161 Phosphorylation
S169 Phosphorylation
S172 Phosphorylation P27361 (MAPK3) , Q16539 (MAPK14) , P45983 (MAPK8) , P53779 (MAPK10)
S175 Phosphorylation
S176 Phosphorylation
S178 Phosphorylation
S179 Phosphorylation
S181 Phosphorylation
S184 Phosphorylation
S187 Phosphorylation
Y197 Phosphorylation
S211 Phosphorylation
S233 Phosphorylation
S237 Phosphorylation
S241 Phosphorylation
S245 Phosphorylation P17612 (PRKACA)
S250 Phosphorylation
S257 Phosphorylation
S261 Phosphorylation
S269 Phosphorylation P17612 (PRKACA)
S278 Phosphorylation
S282 Phosphorylation
S286 Phosphorylation
S290 Phosphorylation
S294 Phosphorylation P17252 (PRKCA) , P17612 (PRKACA)
S324 Phosphorylation
K337 Ubiquitination
S345 Phosphorylation
K349 Sumoylation
S359 Phosphorylation
Y371 Phosphorylation P52333 (JAK3)
K379 Ubiquitination
Y386 Phosphorylation
Y394 Phosphorylation
K398 Ubiquitination
S403 Phosphorylation
S409 Phosphorylation
Y426 Phosphorylation
T504 Phosphorylation
S512 Phosphorylation
S526 Phosphorylation
K538 Ubiquitination
S542 Phosphorylation
K548 Ubiquitination
K612 Acetylation
K626 Acetylation
S670 Phosphorylation
K702 Sumoylation
Y709 Phosphorylation
S765 Phosphorylation
S772 Phosphorylation
S813 Phosphorylation
S887 Phosphorylation
S903 Phosphorylation
T912 Phosphorylation
K914 Sumoylation

Research Backgrounds

Function:

Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2 or IL-4 gene transcription. Also controls gene expression in embryonic cardiac cells. Could regulate not only the activation and proliferation but also the differentiation and programmed death of T-lymphocytes as well as lymphoid and non-lymphoid cells. Required for osteoclastogenesis and regulates many genes important for osteoclast differentiation and function (By similarity).

PTMs:

Phosphorylated by NFATC-kinase and GSK3B; phosphorylation induces NFATC1 nuclear exit and dephosphorylation by calcineurin promotes nuclear import. Phosphorylation by PKA and DYRK2 negatively modulates nuclear accumulation, and promotes subsequent phosphorylation by GSK3B or casein kinase 1.

Subcellular Location:

Cytoplasm. Nucleus.
Note: Cytoplasmic for the phosphorylated form and nuclear after activation that is controlled by calcineurin-mediated dephosphorylation. Rapid nuclear exit of NFATC is thought to be one mechanism by which cells distinguish between sustained and transient calcium signals. The subcellular localization of NFATC plays a key role in the regulation of gene transcription (PubMed:16511445). Nuclear translocation of NFATC1 is enhanced in the presence of TNFSF11. Nuclear translocation is decreased in the presence of FBN1 which can bind and sequester TNFSF11 (By similarity).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in thymus, peripheral leukocytes as T-cells and spleen. Isoforms A are preferentially expressed in effector T-cells (thymus and peripheral leukocytes) whereas isoforms B and isoforms C are preferentially expressed in naive T-cells (spleen). Isoforms B are expressed in naive T-cells after first antigen exposure and isoforms A are expressed in effector T-cells after second antigen exposure. Isoforms IA are widely expressed but not detected in liver nor pancreas, neural expression is strongest in corpus callosum. Isoforms IB are expressed mostly in muscle, cerebellum, placenta and thymus, neural expression in fetal and adult brain, strongest in corpus callosum.

Subunit Structure:

Member of the multicomponent NFATC transcription complex that consists of at least two components, a pre-existing cytoplasmic component NFATC2 and an inducible nuclear component NFATC1. Other members such as NFATC4, NFATC3 or members of the activating protein-1 family, MAF, GATA4 and Cbp/p300 can also bind the complex. NFATC proteins bind to DNA as monomers. Interacts with HOMER2 and HOMER3; this interaction may compete with calcineurin/PPP3CA-binding and hence prevent NFATC1 dephosphorylation and activation.

Family&Domains:

Rel Similarity Domain (RSD) allows DNA-binding and cooperative interactions with AP1 factors.

The N-terminal transactivation domain (TAD-A) binds to and is activated by Cbp/p300. The dephosphorylated form contains two unmasked nuclear localization signals (NLS), which allow translocation of the protein to the nucleus.

Isoforms C have a C-terminal part with an additional trans-activation domain, TAD-B, which acts as a transcriptional activator. Isoforms B have a shorter C-terminal part without complete TAD-B which acts as a transcriptional repressor.

Research Fields

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Wnt signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

· Organismal Systems > Immune system > Th1 and Th2 cell differentiation.   (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

References

1). NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injury. Acta Pharmacologica Sinica, 2021 (PubMed: 34937917) [IF=8.2]

Application: WB    Species: Mouse    Sample: kidney

Fig. 4 11R-VIVIT inhibits the nuclear localization and dephosphorylation of NFAT2 in RTECs in an AKI-to-CKD progression model. a Double immunofluorescence staining of NFAT2 (green) and DAPI (blue) and merged images of kidneys from the sham-operated, IRI and IRI + 11R-VIVIT treatment groups. Scale bars = 20 μm. b Quantification of the percentage of renal tubular epithelial cells with NFAT2 expression in the nucleus. *P 

2). Parathyroid Hormone Promotes Human Umbilical Vein Endothelial Cell Migration and Proliferation Through Orai1-Mediated Calcium Signaling. Frontiers in Cardiovascular Medicine, 2022 (PubMed: 35369318) [IF=3.6]

Application: IF/ICC    Species: Human    Sample: HUVECs

Figure 6 Role of Orai1-mediated store-operated Ca2+ entry (SOCE) in parathyroid hormone (PTH)-induced NFAT nuclear translocation in human umbilical vein endothelial cells (HUVECs). (A–F) Representative confocal microscopy images and summary data (I) showing NFATC1 distribution in HUVECs treated for 24 h with (A) vehicle control, (B) 100 pM PTH, (C) PTH + CsA (calcineurin inhibitor), (D) PTH + W7 (calmodulin antagonist), (E) PTH + BTP2 (an Orai nonspecific inhibitor) or (F) PTH + Orai1 siRNA transfection. Green fluorescence indicates NFATC1; Blue, 4′,6-diamidino-2-phenylindole (DAPI) indicates nuclei. Data are shown as the mean ± SEM; n = 4. **P < 0.01, ***P < 0.001 vs. Con or PTH analyzed by one-way analysis of variance followed by Dunnett's multiple comparisons test. (G,H) Representative Western blot images showing fractionation assay results indicating the presence of p-NFATC1 in the cytoplasmic [Cyto, (H)] and NFATC1 in the nuclear [Nuc, (G)] extracts under the same treatment conditions as for confocal microscopy analyses. Lamin B1 is a nuclear marker; β-Tubulin is a cytoplasmic marker. (I) Summary data showing the ratio of green fluorescence intensity of NFATc-GFP in the nuclear (Nuc)/cytoplasmic (Cyto).

Application: WB    Species: Human    Sample: HUVECs

Figure 6 Role of Orai1-mediated store-operated Ca2+ entry (SOCE) in parathyroid hormone (PTH)-induced NFAT nuclear translocation in human umbilical vein endothelial cells (HUVECs). (A–F) Representative confocal microscopy images and summary data (I) showing NFATC1 distribution in HUVECs treated for 24 h with (A) vehicle control, (B) 100 pM PTH, (C) PTH + CsA (calcineurin inhibitor), (D) PTH + W7 (calmodulin antagonist), (E) PTH + BTP2 (an Orai nonspecific inhibitor) or (F) PTH + Orai1 siRNA transfection. Green fluorescence indicates NFATC1; Blue, 4′,6-diamidino-2-phenylindole (DAPI) indicates nuclei. Data are shown as the mean ± SEM; n = 4. **P < 0.01, ***P < 0.001 vs. Con or PTH analyzed by one-way analysis of variance followed by Dunnett's multiple comparisons test. (G,H) Representative Western blot images showing fractionation assay results indicating the presence of p-NFATC1 in the cytoplasmic [Cyto, (H)] and NFATC1 in the nuclear [Nuc, (G)] extracts under the same treatment conditions as for confocal microscopy analyses. Lamin B1 is a nuclear marker; β-Tubulin is a cytoplasmic marker. (I) Summary data showing the ratio of green fluorescence intensity of NFATc-GFP in the nuclear (Nuc)/cytoplasmic (Cyto).

Application: WB    Species: human    Sample: HUVECs

FIGURE 6 | Role of Orai1-mediated store-operated Ca2+ entry (SOCE) in parathyroid hormone (PTH)-induced NFAT nuclear translocation in human umbilical vein endothelial cells (HUVECs).(G,H) Representative Western blot images showing fractionation assay results indicating the presence of p-NFATC1 in the cytoplasmic

3). Calcium Channel Blocker Nifedipine Suppresses Colorectal Cancer Progression and Immune Escape by Preventing NFAT2 Nuclear Translocation. , 2020

Application: WB    Species: Human    Sample: T cells

Figure 6. NIFE Inhibits the Expression of PD-1 on T Cells in an NFAT2-Dependent Manner In Vitro and In Vivo (A) Left panel: the expression of PD-1 in peripheral blood mononuclear cells (PBMCs) treated with NIFE was detected by qPCR. Right panel: the expression of PD1 in PBMCs transfected with NFAT2 siRNA was detected by qPCR. (B) Upper panel: the transcriptional regulation of PD-1 by NFAT2 and p-STAT3 was detected by ChIP. Lower panel: the expression of p-NFAT2 and CAMK-IV in the indicated PBMCs was detected by WB. (C) The binding sites between NFAT2 and the PD-1 promoter were confirmed by a dual-luciferase reporter system. (D) The relationship between NFAT2 and PD-1 in human T cells was detected from the GEO database (GEO: GSE56580). (E) The percentages of PD-1+ T cells (upper panels) and PD-1+ CD8+ T cells (lower panels) in peripheral T cells from CRC patients treated with NIFE were detected by flow cytometry sorting. (F) The percentages of PD-1+ T cells (upper panels) and PD-1+ CD8+ T cells (lower panels) in peripheral T cells from healthy people treated with NIFE and cocultured with SW620 cells were detected by flow cytometry sorting.

4). Neuromedin U Induces Pulmonary Group 2 Innate Lymphoid Cell Activation via NMUR1 Pathway During Acute Respiratory Syncytial Virus Infection. Research Square, 2021

Application: WB    Species: Mouse    Sample: lung

Figure 7. NMU regulates ILC2 activation via PI3K/NFAT and MEK/NFAT signals. ILC2s were sorted from the lungs of mice on day 3 after RSV infection, and co-cultured with NMU in vitro in the presence or absence of signal inhibitors. A-C Expressions of IL-5 and IL-13 by Real-time PCR in the presence of MEK inhibitor U0126-EtOH (A), PI3K inhibitor LY294002 (B), and NFAT inhibitor 11R-VIVIT (C). D-E Concentrations of IL-5 and IL-13 in the culture supernatants of pulmonary ILC2s were determined by ELISA in the presence of MEK inhibitor U0126-EtOH (D), PI3K inhibitor LY294002 (E), and NFAT inhibitor 11R-VIVIT (F). G-H The expression of signal proteins in the isolated ILC2s were determined by Western blot under the conditions of the presence or absence of U0126-EtOH (G) or LY294002 (H). Data are representative of at least two individual experiments, error bars represent SEM;

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.